| 会社名 | Group | 親会社 | 子会社 | 得意先 | 仕入先 | 業務提携 | 銀行等 | 株主等 |
|---|---|---|---|---|---|---|---|---|
| Xellia | ||||||||
| Scheider Electric Advisory Services | ||||||||
| All Hands and Hearts | ||||||||
| Americares | ||||||||
| Association of Accessible Medicines | ||||||||
| Baheya Foundation | ||||||||
| 百奥泰生物制药股份有限公司 | ||||||||
| Celltrion | ||||||||
| Clothing Bank | ||||||||
| Direct Relief | ||||||||
|
|
||||||||
|
|
||||||||
| Global Smile Foundation | ||||||||
| Habaybna.net | ||||||||
| IndX | ||||||||
| King Hussein Cancer Foundation | ||||||||
| Medical Aid for Palestinians | ||||||||
| National Children’s Cancer Society | ||||||||
| Royal Health Awareness Society | ||||||||
| SAP | ||||||||
| The Emergency Assistance Center | ||||||||
| Tkiyet Um Ali | ||||||||
| United Nations High Commissioner for Refugees | ||||||||
| pharma& |
We were founded in Jordan in 1978, where we established ourselves as a leading supplier of branded generics and in-licensed products.
Founded in 1978, Hikma is now a global pharmaceutical company serving patients across North America, the MENA region and Europe, and a leader in generics and specialty medicines grounded in quality and reliability.
Hikma was founded in 1978 in Amman, Jordan by Samih Darwazah.
In 2005, the Group listed on the London Stock Exchange, raising gross proceeds of US$124 million.
Hikma Pharmaceuticals listed on the London Stock Exchange in 2005.
In 2020, our new high containment facility received US FDA approval.
On 15 December 2025 Riad Mishlawi stepped down as CEO and Said Darwazah, Executive Chairman and former CEO, assumed the CEO responsibilities.
Hikma Pharmaceuticals announced the US launch of Deflazacort Tablets in four strengths: 6 mg, 18 mg, 30 mg and 36 mg. The medicine is indicated for Duchenne muscular dystrophy in patients aged 2 years and older.
Lama Shatara, Hikma’s Senior Director of Business Development & Alliance Management for MENA, shares her transition from regulatory affairs to business development and outlines her role in licensing activities across the region. She highlights how strategic partnerships are driving Hikma’s pipeline growth and discusses the leadership principles that guide her career.
Hikma Pharmaceuticals PLC announced that Rebecca Hall will join as CFO and executive director in the first quarter of 2027. Hall previously served as CFO of ViiV Healthcare, a GSK subsidiary.
Hikma Pharmaceuticals announced a series of three educational investor seminars focused on its R&D strategy and capabilities. The company plans to increase R&D investment to around 5-6% of revenue. The seminars will highlight Hikma's efforts to strengthen its global pipeline and support long-term growth, focusing on three key R&D pillars.
Dima Freihat is responsible for research and development and product transfer of solid oral dosage forms in Hikma's R&D, supporting the transition from research to commercial production. She speaks about the collaboration and motivation needed for the successful launch of products.
Hikma Pharmaceuticals launched Glucentra, the first generic semaglutide product in Saudi Arabia. This improves patient access.
As part of a series introducing Hikma employees, Ana Catarina Costa was featured. Her story provides insight into Hikma's culture, collaboration and sense of purpose.
Hikma Pharmaceuticals announced that filings for regulatory review of its epinephrine nasal spray for the emergency treatment of allergic reactions were accepted in the US, Europe and the UK. It has also filed in Canada and plans to expand to other markets in the future.
Mohammad Al Hiribat, a Principal Scientist in formulation development at Hikma's Jordan site, is involved in new product launches and technology transfer. He spoke about the challenges of moving from development to commercial production and what inspires his work.
Hikma Pharmaceuticals signed its first Virtual Power Purchase Agreement (VPPA) with Q ENERGY. The agreement supports a 34.6 MWp solar power plant to be built near Madrid, Spain, from 2027, and is an important step toward the target of reducing Scope 2 emissions by 25% by 2030 compared with 2020.